-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Medical Network News on May 14
Heavy variety, the first imitation is nearly
On May 12, the official website of the Center for Drug Evaluation of the National Medical Products Administration showed that Jiangsu Wanbang Biochemical 's application for the listing of generic drugs for Ochinib mesylate tablets has been accepted, and the first imitation is expected.
Osimertinib is an irreversible third-generation EGFR tyrosine kinase inhibitor, developed by AstraZeneca.
So far, it has been approved for three indications in China.
They are used for the second-line treatment of NSCLC with EGFR T790M mutation, and It is the first-line treatment for EGFRm NSCLC and the adjuvant treatment for EGFR-mutant lung cancer patients.
At present, the first two indications have entered the national medical insurance catalog.
So far, it has been approved for three indications in China.
They are used for the second-line treatment of NSCLC with EGFR T790M mutation, and It is the first-line treatment for EGFRm NSCLC and the adjuvant treatment for EGFR-mutant lung cancer patients.
At present, the first two indications have entered the national medical insurance catalog.
Osimertinib entered the Chinese market in 2017 with the product name Teresa, contributing more than 500 million yuan in revenue within 9 months, and was included in the national medical insurance in 2018.
In 2020, the medical insurance negotiation was successful, and the medical insurance payment price was 5580 yuan/ Box (original price 15300/box), the price reduction rate reaches 63.
5%.
In 2020, the medical insurance negotiation was successful, and the medical insurance payment price was 5580 yuan/ Box (original price 15300/box), the price reduction rate reaches 63.
5%.
As the star drug of AstraZeneca, osimertinib has maintained rapid growth in recent years.
AstraZeneca's 2020 annual report shows that sales of osimertinib reached US$4.
328 billion, an increase of 36%.
In fact, there are opinions in the industry that osimertinib should be one of the most famous imported anti-cancer drugs that have been on the market in recent years and has the greatest impact on Chinese patients.
AstraZeneca's 2020 annual report shows that sales of osimertinib reached US$4.
328 billion, an increase of 36%.
In fact, there are opinions in the industry that osimertinib should be one of the most famous imported anti-cancer drugs that have been on the market in recent years and has the greatest impact on Chinese patients.
Public information shows that Jiangsu Wanbang Biochemical Group Co.
, Ltd.
, which has applied for the first imitation of Osimertinib, is a core member company of Shanghai Fosun Pharma .
Its representative products include Ulitone®, Cestbon, etc.
, in addition to Keyi®, Exclusive varieties such as Kesheng®.
, Ltd.
, which has applied for the first imitation of Osimertinib, is a core member company of Shanghai Fosun Pharma .
Its representative products include Ulitone®, Cestbon, etc.
, in addition to Keyi®, Exclusive varieties such as Kesheng®.
It is worth noting that the Insight database shows that the patent of Osimertinib will not expire in China until 2032.
The impact of the acceptance of the first generic drug on Osimertinib may take some time to be reflected.
The impact of the acceptance of the first generic drug on Osimertinib may take some time to be reflected.
intense market competition
At present, lung cancer is the type of cancer with the highest incidence in my country, and EGFR is one of the main targets for the treatment of lung cancer patients in China.
Studies have shown that my country's EGFR-TKI drug market is expected to reach 18.
27 billion yuan in 2023, with a compound annual growth rate of 22.
9% during the period.
Studies have shown that my country's EGFR-TKI drug market is expected to reach 18.
27 billion yuan in 2023, with a compound annual growth rate of 22.
9% during the period.
The third-generation drugs have a relatively good market share in the EGFR-TKI drug market.
Research shows that the market share of first-generation drugs in 2018 was 57%, second-generation drugs only accounted for 5%, and third-generation EGFR-TKI drugs reached 38%.
It is expected that by 2023, the share of third-generation drugs will increase to 50%-60%.
Therefore, the market size of corresponding third-generation EGFR-TKI drugs is approximately 9.
14 billion yuan to 10.
96 billion yuan.
Research shows that the market share of first-generation drugs in 2018 was 57%, second-generation drugs only accounted for 5%, and third-generation EGFR-TKI drugs reached 38%.
It is expected that by 2023, the share of third-generation drugs will increase to 50%-60%.
Therefore, the market size of corresponding third-generation EGFR-TKI drugs is approximately 9.
14 billion yuan to 10.
96 billion yuan.
At present, the first-generation EGFR-TKI is represented by gefitinib, icotinib and erlotinib, the second-generation EGFR-TKI is represented by afatinib and dacomitinib, and osimertinib It is the product with far leading sales in the third generation.
However, although osimertinib is the market leader of the third-generation EGFR-TKI, the competitive situation is not optimistic.
On the one hand, it is the sales pressure brought about by the sharp price cuts.
On the other hand, the current domestic three-generation EGFR-TKI has been highly competitive.
On the one hand, it is the sales pressure brought about by the sharp price cuts.
On the other hand, the current domestic three-generation EGFR-TKI has been highly competitive.
Public information shows that, in addition to osimertinib, two domestic drugs, Ametinib from Hausen and Vometinib from Iris Medical, have been approved for marketing.
In addition, according to the Insight database, Avitinib from Aisen Biotech, Befortinib from Betta Pharmaceuticals, and Rezetinib from CSPC/Beida have also been reported for production.
In addition, according to the Insight database, Avitinib from Aisen Biotech, Befortinib from Betta Pharmaceuticals, and Rezetinib from CSPC/Beida have also been reported for production.
Among them, Ametinib has entered the 2020 version of the medical insurance catalog, and the price has dropped from 360,000 yuan per year to 30,000 yuan.
The CEO of Iris Mou Yanping is also very optimistic about the prospects of vomitinib.
He once said: "It is expected to be in 2023.
The sales can reach 18.
3-27.
4 billion yuan.
"
The CEO of Iris Mou Yanping is also very optimistic about the prospects of vomitinib.
He once said: "It is expected to be in 2023.
The sales can reach 18.
3-27.
4 billion yuan.
"
In general, it remains to be seen what changes will occur in the future market conditions of Osimertinib.
Several first generic drugs launched
Toremifene citrate
Toremifene citrate is an estrogen receptor antagonist anti-tumor drug, used for postmenopausal women with estrogen receptor positive or unknown metastatic breast cancer, and is a national medical insurance class B drug.
At present, only one imported and one domestic preparation of this product has been approved for marketing in China, and no other company has launched generic drug declaration work.
At present, only one imported and one domestic preparation of this product has been approved for marketing in China, and no other company has launched generic drug declaration work.
Shiyao Ouyi's Doxorubicin Hydrochloride Liposome Injection
Doxorubicin hydrochloride liposome injection is an important chemotherapy drug for multiple myeloma, lymphoma, ovarian cancer, breast cancer and other important chemotherapy drugs.
In 2019, the terminal sales of medical institutions in China was 1.
854 billion yuan, a year-on-year increase of 70.
84%.
bright future.
At present, there are 3 domestic companies approved to produce the drug, including CSPC Ouyi, Jinyuan Pharmaceutical and Shanghai Fudan Zhangjiang.
CSPC Ouyi has the highest share, occupying 59.
49% of the market.
In 2019, the terminal sales of medical institutions in China was 1.
854 billion yuan, a year-on-year increase of 70.
84%.
bright future.
At present, there are 3 domestic companies approved to produce the drug, including CSPC Ouyi, Jinyuan Pharmaceutical and Shanghai Fudan Zhangjiang.
CSPC Ouyi has the highest share, occupying 59.
49% of the market.
In the context of accelerating the replacement of the original research by the first imitations in China, it remains to be seen what impact these first generic drugs will have on the original research market.
Medical Network News on May 14
Heavy variety, the first imitation is nearly
On May 12, the official website of the Center for Drug Evaluation of the National Medical Products Administration showed that Jiangsu Wanbang Biochemical 's application for the listing of generic drugs for Ochinib mesylate tablets has been accepted, and the first imitation is expected.
Osimertinib is an irreversible third-generation EGFR tyrosine kinase inhibitor, developed by AstraZeneca.
So far, it has been approved for three indications in China.
They are used for the second-line treatment of NSCLC with EGFR T790M mutation, and It is the first-line treatment for EGFRm NSCLC and the adjuvant treatment for EGFR-mutant lung cancer patients.
At present, the first two indications have entered the national medical insurance catalog.
So far, it has been approved for three indications in China.
They are used for the second-line treatment of NSCLC with EGFR T790M mutation, and It is the first-line treatment for EGFRm NSCLC and the adjuvant treatment for EGFR-mutant lung cancer patients.
At present, the first two indications have entered the national medical insurance catalog.
Osimertinib entered the Chinese market in 2017 with the product name Teresa, contributing more than 500 million yuan in revenue within 9 months, and was included in the national medical insurance in 2018.
In 2020, the medical insurance negotiation was successful, and the medical insurance payment price was 5580 yuan/ Box (original price 15300/box), the price reduction rate reaches 63.
5%.
In 2020, the medical insurance negotiation was successful, and the medical insurance payment price was 5580 yuan/ Box (original price 15300/box), the price reduction rate reaches 63.
5%.
As the star drug of AstraZeneca, osimertinib has maintained rapid growth in recent years.
AstraZeneca's 2020 annual report shows that sales of osimertinib reached US$4.
328 billion, an increase of 36%.
In fact, there are opinions in the industry that osimertinib should be one of the most famous imported anti-cancer drugs that have been on the market in recent years and has the greatest impact on Chinese patients.
AstraZeneca's 2020 annual report shows that sales of osimertinib reached US$4.
328 billion, an increase of 36%.
In fact, there are opinions in the industry that osimertinib should be one of the most famous imported anti-cancer drugs that have been on the market in recent years and has the greatest impact on Chinese patients.
Public information shows that Jiangsu Wanbang Biochemical Group Co.
, Ltd.
, which has applied for the first imitation of Osimertinib, is a core member company of Shanghai Fosun Pharma .
Its representative products include Ulitone®, Cestbon, etc.
, in addition to Keyi®, Exclusive varieties such as Kesheng®.
, Ltd.
, which has applied for the first imitation of Osimertinib, is a core member company of Shanghai Fosun Pharma .
Its representative products include Ulitone®, Cestbon, etc.
, in addition to Keyi®, Exclusive varieties such as Kesheng®.
It is worth noting that the Insight database shows that the patent of Osimertinib will not expire in China until 2032.
The impact of the acceptance of the first generic drug on Osimertinib may take some time to be reflected.
The impact of the acceptance of the first generic drug on Osimertinib may take some time to be reflected.
intense market competition
At present, lung cancer is the type of cancer with the highest incidence in my country, and EGFR is one of the main targets for the treatment of lung cancer patients in China.
Studies have shown that my country's EGFR-TKI drug market is expected to reach 18.
27 billion yuan in 2023, with a compound annual growth rate of 22.
9% during the period.
Studies have shown that my country's EGFR-TKI drug market is expected to reach 18.
27 billion yuan in 2023, with a compound annual growth rate of 22.
9% during the period.
The third-generation drugs have a relatively good market share in the EGFR-TKI drug market.
Research shows that the market share of first-generation drugs in 2018 was 57%, second-generation drugs only accounted for 5%, and third-generation EGFR-TKI drugs reached 38%.
It is expected that by 2023, the share of third-generation drugs will increase to 50%-60%.
Therefore, the market size of corresponding third-generation EGFR-TKI drugs is approximately 9.
14 billion yuan to 10.
96 billion yuan.
Research shows that the market share of first-generation drugs in 2018 was 57%, second-generation drugs only accounted for 5%, and third-generation EGFR-TKI drugs reached 38%.
It is expected that by 2023, the share of third-generation drugs will increase to 50%-60%.
Therefore, the market size of corresponding third-generation EGFR-TKI drugs is approximately 9.
14 billion yuan to 10.
96 billion yuan.
At present, the first-generation EGFR-TKI is represented by gefitinib, icotinib and erlotinib, the second-generation EGFR-TKI is represented by afatinib and dacomitinib, and osimertinib It is the product with far leading sales in the third generation.
However, although osimertinib is the market leader of the third-generation EGFR-TKI, the competitive situation is not optimistic.
On the one hand, it is the sales pressure brought about by the sharp price cuts.
On the other hand, the current domestic three-generation EGFR-TKI has been highly competitive.
On the one hand, it is the sales pressure brought about by the sharp price cuts.
On the other hand, the current domestic three-generation EGFR-TKI has been highly competitive.
Public information shows that, in addition to osimertinib, two domestic drugs, Ametinib from Hausen and Vometinib from Iris Medical, have been approved for marketing.
In addition, according to the Insight database, Avitinib from Aisen Biotech, Befortinib from Betta Pharmaceuticals, and Rezetinib from CSPC/Beida have also been reported for production.
In addition, according to the Insight database, Avitinib from Aisen Biotech, Befortinib from Betta Pharmaceuticals, and Rezetinib from CSPC/Beida have also been reported for production.
Among them, Ametinib has entered the 2020 version of the medical insurance catalog, and the price has dropped from 360,000 yuan per year to 30,000 yuan.
The CEO of Iris Mou Yanping is also very optimistic about the prospects of vomitinib.
He once said: "It is expected to be in 2023.
The sales can reach 18.
3-27.
4 billion yuan.
"
The CEO of Iris Mou Yanping is also very optimistic about the prospects of vomitinib.
He once said: "It is expected to be in 2023.
The sales can reach 18.
3-27.
4 billion yuan.
"
In general, it remains to be seen what changes will occur in the future market conditions of Osimertinib.
Several first generic drugs launched
Toremifene citrate
Toremifene citrate is an estrogen receptor antagonist anti-tumor drug, used for postmenopausal women with estrogen receptor positive or unknown metastatic breast cancer, and is a national medical insurance class B drug.
At present, only one imported and one domestic preparation of this product has been approved for marketing in China, and no other company has launched generic drug declaration work.
At present, only one imported and one domestic preparation of this product has been approved for marketing in China, and no other company has launched generic drug declaration work.
Shiyao Ouyi's Doxorubicin Hydrochloride Liposome Injection
Doxorubicin hydrochloride liposome injection is an important chemotherapy drug for multiple myeloma, lymphoma, ovarian cancer, breast cancer and other important chemotherapy drugs.
In 2019, the terminal sales of medical institutions in China was 1.
854 billion yuan, a year-on-year increase of 70.
84%.
bright future.
At present, there are 3 domestic companies approved to produce the drug, including CSPC Ouyi, Jinyuan Pharmaceutical and Shanghai Fudan Zhangjiang.
CSPC Ouyi has the highest share, occupying 59.
49% of the market.
In 2019, the terminal sales of medical institutions in China was 1.
854 billion yuan, a year-on-year increase of 70.
84%.
bright future.
At present, there are 3 domestic companies approved to produce the drug, including CSPC Ouyi, Jinyuan Pharmaceutical and Shanghai Fudan Zhangjiang.
CSPC Ouyi has the highest share, occupying 59.
49% of the market.
In the context of accelerating the replacement of the original research by the first imitations in China, it remains to be seen what impact these first generic drugs will have on the original research market.
Medical Network News on May 14
Heavy variety, the first imitation is nearly
Heavy variety, the first imitation is nearly On May 12, the official website of the Center for Drug Evaluation of the National Medical Products Administration showed that Jiangsu Wanbang Biochemical 's application for the listing of generic drugs for Ochinib mesylate tablets has been accepted, and the first imitation is expected.
Medicine Medicine Medicine Osimertinib is an irreversible third-generation EGFR tyrosine kinase inhibitor, developed by AstraZeneca.
So far, it has been approved for three indications in China.
They are used for the second-line treatment of NSCLC with EGFR T790M mutation, and It is the first-line treatment for EGFRm NSCLC and the adjuvant treatment for EGFR-mutant lung cancer patients.
At present, the first two indications have entered the national medical insurance catalog.
So far, it has been approved for three indications in China.
They are used for the second-line treatment of NSCLC with EGFR T790M mutation, and It is the first-line treatment for EGFRm NSCLC and the adjuvant treatment for EGFR-mutant lung cancer patients.
At present, the first two indications have entered the national medical insurance catalog.
Osimertinib entered the Chinese market in 2017 with the product name Teresa, contributing more than 500 million yuan in revenue within 9 months, and was included in the national medical insurance in 2018.
In 2020, the medical insurance negotiation was successful, and the medical insurance payment price was 5580 yuan/ Box (original price 15300/box), the price reduction rate reaches 63.
5%.
In 2020, the medical insurance negotiation was successful, and the medical insurance payment price was 5580 yuan/ Box (original price 15300/box), the price reduction rate reaches 63.
5%.
As the star drug of AstraZeneca, osimertinib has maintained rapid growth in recent years.
AstraZeneca's 2020 annual report shows that sales of osimertinib reached US$4.
328 billion, an increase of 36%.
In fact, there are opinions in the industry that osimertinib should be one of the most famous imported anti-cancer drugs that have been on the market in recent years and has the greatest impact on Chinese patients.
AstraZeneca's 2020 annual report shows that sales of osimertinib reached US$4.
328 billion, an increase of 36%.
In fact, there are opinions in the industry that osimertinib should be one of the most famous imported anti-cancer drugs that have been on the market in recent years and has the greatest impact on Chinese patients.
Public information shows that Jiangsu Wanbang Biochemical Group Co.
, Ltd.
, which has applied for the first imitation of Osimertinib, is a core member company of Shanghai Fosun Pharma .
Its representative products include Ulitone®, Cestbon, etc.
, in addition to Keyi®, Exclusive varieties such as Kesheng®.
Enterprise business enterprise, Ltd.
, which has applied for the first imitation of Osimertinib, is a core member company of Shanghai Fosun Pharma .
Its representative products include Ulitone®, Cestbon, etc.
, in addition to Keyi®, Exclusive varieties such as Kesheng®.
It is worth noting that the Insight database shows that the patent of Osimertinib will not expire in China until 2032.
The impact of the acceptance of the first generic drug on Osimertinib may take some time to be reflected.
The impact of the acceptance of the first generic drug on Osimertinib may take some time to be reflected.
intense market competition
intense market competition At present, lung cancer is the type of cancer with the highest incidence in my country, and EGFR is one of the main targets for the treatment of lung cancer patients in China.
Studies have shown that my country's EGFR-TKI drug market is expected to reach 18.
27 billion yuan in 2023, with a compound annual growth rate of 22.
9% during the period.
Studies have shown that my country's EGFR-TKI drug market is expected to reach 18.
27 billion yuan in 2023, with a compound annual growth rate of 22.
9% during the period.
The third-generation drugs have a relatively good market share in the EGFR-TKI drug market.
Research shows that the market share of first-generation drugs in 2018 was 57%, second-generation drugs only accounted for 5%, and third-generation EGFR-TKI drugs reached 38%.
It is expected that by 2023, the share of third-generation drugs will increase to 50%-60%.
Therefore, the market size of corresponding third-generation EGFR-TKI drugs is approximately 9.
14 billion yuan to 10.
96 billion yuan.
Research shows that the market share of first-generation drugs in 2018 was 57%, second-generation drugs only accounted for 5%, and third-generation EGFR-TKI drugs reached 38%.
It is expected that by 2023, the share of third-generation drugs will increase to 50%-60%.
Therefore, the market size of corresponding third-generation EGFR-TKI drugs is approximately 9.
14 billion yuan to 10.
96 billion yuan.
At present, the first-generation EGFR-TKI is represented by gefitinib, icotinib and erlotinib, the second-generation EGFR-TKI is represented by afatinib and dacomitinib, and osimertinib It is the product with far leading sales in the third generation.
However, although osimertinib is the market leader of the third-generation EGFR-TKI, the competitive situation is not optimistic.
On the one hand, it is the sales pressure brought about by the sharp price cuts.
On the other hand, the current domestic three-generation EGFR-TKI has been highly competitive.
On the one hand, it is the sales pressure brought about by the sharp price cuts.
On the other hand, the current domestic three-generation EGFR-TKI has been highly competitive.
Public information shows that, in addition to osimertinib, two domestic drugs, Ametinib from Hausen and Vometinib from Iris Medical, have been approved for marketing.
In addition, according to the Insight database, Avitinib from Aisen Biotech, Befortinib from Betta Pharmaceuticals, and Rezetinib from CSPC/Beida have also been reported for production.
In addition, according to the Insight database, Avitinib from Aisen Biotech, Befortinib from Betta Pharmaceuticals, and Rezetinib from CSPC/Beida have also been reported for production.
Among them, Ametinib has entered the 2020 version of the medical insurance catalog, and the price has dropped from 360,000 yuan per year to 30,000 yuan.
The CEO of Iris Mou Yanping is also very optimistic about the prospects of vomitinib.
He once said: "It is expected to be in 2023.
The sales can reach 18.
3-27.
4 billion yuan.
"
The CEO of Iris Mou Yanping is also very optimistic about the prospects of vomitinib.
He once said: "It is expected to be in 2023.
The sales can reach 18.
3-27.
4 billion yuan.
"
In general, it remains to be seen what changes will occur in the future market conditions of Osimertinib.
Several first generic drugs launched
Several first generic drugs launched Toremifene citrate
Toremifene citrate Toremifene citrate is an estrogen receptor antagonist anti-tumor drug, used for postmenopausal women with estrogen receptor positive or unknown metastatic breast cancer, and is a national medical insurance class B drug.
At present, only one imported and one domestic preparation of this product has been approved for marketing in China, and no other company has launched generic drug declaration work.
At present, only one imported and one domestic preparation of this product has been approved for marketing in China, and no other company has launched generic drug declaration work.
Shiyao Ouyi's Doxorubicin Hydrochloride Liposome Injection
Shiyao Ouyi's Doxorubicin Hydrochloride Liposome Injection Doxorubicin hydrochloride liposome injection is an important chemotherapy drug for multiple myeloma, lymphoma, ovarian cancer, breast cancer and other important chemotherapy drugs.
In 2019, the terminal sales of medical institutions in China was 1.
854 billion yuan, a year-on-year increase of 70.
84%.
bright future.
At present, there are 3 domestic companies approved to produce the drug, including CSPC Ouyi, Jinyuan Pharmaceutical and Shanghai Fudan Zhangjiang.
CSPC Ouyi has the highest share, occupying 59.
49% of the market.
In 2019, the terminal sales of medical institutions in China was 1.
854 billion yuan, a year-on-year increase of 70.
84%.
bright future.
At present, there are 3 domestic companies approved to produce the drug, including CSPC Ouyi, Jinyuan Pharmaceutical and Shanghai Fudan Zhangjiang.
CSPC Ouyi has the highest share, occupying 59.
49% of the market.
In the context of accelerating the replacement of the original research by the first imitations in China, it remains to be seen what impact these first generic drugs will have on the original research market.
